Trending...
- The New Monaco of the South (of Italy)
- FrostSkin Launches Kickstarter Campaign for Patent-Pending Instant-Chill Water Purification Bottle
- OctoNerv Completes Functional Prototype of Electronic Breast Nipple Implant (EBNI)
BOSTON, May 20, 2024 ~ Journalist: HotSpot Therapeutics, Inc. has announced that they will be presenting additional preclinical data from their MALT1 program at the 4th American Association for Cancer Research (AACR) International Meeting. The meeting, titled "Advances in Malignant Lymphoma," will take place from June 19-22, 2024 in Philadelphia, PA.
The company, known for pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," will be sharing their findings on the highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program.
More on The PennZone
The presentation, titled "Targeting the CBM Signalosome with a MALT1 Scaffolding Inhibitor for Treatment of Non-Hodgkin Lymphomas," will take place on Thursday, June 20, 2024 from 5:30-7:30 PM ET at the Sheraton Philadelphia Downtown. The publication number for this presentation is PO-036.
HotSpot Therapeutics' innovative approach to targeting regulatory sites on proteins has shown promising results in their MALT1 program and could potentially lead to new treatments for non-Hodgkin lymphomas. The company's participation in the AACR International Meeting highlights their commitment to advancing cancer research and finding new ways to treat this disease.
The company, known for pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," will be sharing their findings on the highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program.
More on The PennZone
- $1 Million Share Repurchase Signals Confidence as Off The Hook YS Scales a Tech-Driven Platform in the $57 Billion U.S. Marine Market
- Trends Journal's Top Trends of 2026
- CollabWait to Launch Innovative Waitlist Management Platform for Behavioral Health Services
- Urban Bush Women Celebrates Bessie Award Nominations & Winter 2026 Touring
- Imagen Golf Launches "Precision Lessons" with Trackman iO in Newtown, PA
The presentation, titled "Targeting the CBM Signalosome with a MALT1 Scaffolding Inhibitor for Treatment of Non-Hodgkin Lymphomas," will take place on Thursday, June 20, 2024 from 5:30-7:30 PM ET at the Sheraton Philadelphia Downtown. The publication number for this presentation is PO-036.
HotSpot Therapeutics' innovative approach to targeting regulatory sites on proteins has shown promising results in their MALT1 program and could potentially lead to new treatments for non-Hodgkin lymphomas. The company's participation in the AACR International Meeting highlights their commitment to advancing cancer research and finding new ways to treat this disease.
Filed Under: Business
0 Comments
Latest on The PennZone
- The Stork Foundation Announces 2025 Year-End Impact and Grant Awards Amid Rising National Demand
- Stout Industrial Technology Appoints Paul Bonnett as Chief Executive Officer
- Revenue Optics Appoints Ljupco Icevski as Executive Advisor in Strategic Move to Accelerate Commercial Development
- Syntax of Sorrow: An Exhibition Examining Synthetic Affliction in the Age of Artificial Intelligence
- Waarom brand mentions in ChatGPT steeds belangrijker worden
- Yunishigawa Onsen's Annual "Kamakura Festival" will be held January 30 – March 1, 2026
- At Your Service Plumbing Named a 2025 Nextdoor Neighborhood Fave
- Custom Home Builder Connecticut Valley Homes Wins 2025 Home of the Year from the Modular Home Builders Association
- Insight Holistic Imaging Introduces In-LightN Advanced Thermography - New Personalized Wellness Scr
- TrueNorth Wellness Services Welcomes a New CEO
- Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
- Breakout Phase for Public Company: New Partnerships, Zero Debt, and $20 Million Growth Capital Position Company for 2026 Acceleration
- Japan's Patented "Hammock'n" Smartphone Band Targets Hand Fatigue From Long Phone Use
- Reditus Group Introduces A New Empirical Model for Early-Stage B2B Growth
- CCHR: Harvard Review Exposes Institutional Corruption in Global Mental Health
- Goatimus Launches Dynamic Context: AI Prompt Engineering Gets Smarter
- Global License Exclusive Secured for Emesyl OTC Nausea Relief, Expanding Multi-Product Growth Strategy for Caring Brands, Inc. (N A S D A Q: CABR)
- RNHA Affirms Support for President Trump as Nation Marks Historic Victory for Freedom
- American Laser Study Club Announces 2026 Kumar Patel Prize in Laser Surgery Recipients: Ann Bynum, DDS, and Boaz Man, DVM